← Back to Search

Other

T4090 vs Rhopressa for Glaucoma

Phase 2
Recruiting
Research Sponsored by Laboratoires Thea
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patient (male or female) ≥18 years old
Patient with Open Angle Glaucoma or Ocular Hypertension in both eyes
Must not have
Secondary Open Angle Glaucoma (ex. Pseudoexfoliation, Pigmentary glaucoma)
Advanced stage of glaucoma
Timeline
Screening 3 weeks
Treatment Varies
Follow Up the primary efficacy endpoint is the change from baseline (d1) at week 7 in the mean diurnal iop in the study eye.
Awards & highlights

Summary

This trial aims to compare the effectiveness and safety of two different concentrations of T4090 eye drops (0.2% and 0.3%) with Rhopressa® eye drops in reducing

Who is the study for?
This trial is for adults over 18 with Open-Angle Glaucoma or Ocular Hypertension in both eyes. Participants must understand the study and sign a consent form.
What is being tested?
The trial aims to compare the effectiveness and safety of two concentrations (0.2% and 0.3%) of T4090 ophthalmic solution against Rhopressa® in reducing eye pressure.
What are the potential side effects?
Potential side effects may include mild to moderate eye irritation, redness, discomfort, or blurred vision similar to other glaucoma medications.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I have been diagnosed with glaucoma or high eye pressure in both eyes.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a specific type of glaucoma not caused by an eye injury.
Select...
My glaucoma is in an advanced stage.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~the primary efficacy endpoint is the change from baseline (d1) at week 7 in the mean diurnal iop in the study eye.
This trial's timeline: 3 weeks for screening, Varies for treatment, and the primary efficacy endpoint is the change from baseline (d1) at week 7 in the mean diurnal iop in the study eye. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
IOP Assessment

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: T4090 0.3%Experimental Treatment1 Intervention
Group II: T4090 0.2%Experimental Treatment1 Intervention
Group III: Rhopressa®Active Control1 Intervention

Find a Location

Who is running the clinical trial?

Laboratoires TheaLead Sponsor
57 Previous Clinical Trials
6,665 Total Patients Enrolled
9 Trials studying Glaucoma
2,311 Patients Enrolled for Glaucoma
~84 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top